Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290508 · ClinicalTrials.gov registry record
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 524
- Enrollment target
NCT03290508: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT03290508 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 524 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03290508 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 524 participants
- Enrollment target
Study Summary
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.
Interventions
- DIAGNOSTIC_TEST Prolaris Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 524 participants |
| Start Date | 2017-09-14 |
| Est. Completion | 2022-01-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03290508
The ClinicalTrials.gov registry entry for NCT03290508 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 524 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prolaris Testing is the first listed.
NCT03290508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03290508 about?
NCT03290508 is a clinical study titled "Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer". This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient onc...
What is the current status of trial NCT03290508?
This trial is currently terminated. The enrollment target is 524 participants. The study started on 2017-09-14. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT03290508?
The interventions under investigation include: Prolaris Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03290508?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.